Extended Use of the Wearable Cardioverter-Defibrillator: Which Patients Are Most Likely to Benefit?
Boldizsar Kovacs(University of Michigan), Fırat Duru(University of Malta), Urs Eriksson(GZO Spital Wetzikon), Nazmi Krasniqi(GZO Spital Wetzikon), Sven Reek(Hirslanden Klinik Aarau)
Cited by 10
Related Papers
Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases
|European Heart Journal|2021|1.1k
Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology <scp>W</scp> orking <scp>G</scp> roup on <scp>M</scp> yocardial and <scp>P</scp> ericardial <scp>D</scp> iseases
|European Journal of Heart Failure|2021|330
Diagnosis and management of myocardial involvement in systemic immune-mediated diseases: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease
|European Heart Journal|2017|263
Midkine drives cardiac inflammation by promoting neutrophil trafficking and NETosis in myocarditis
|The Journal of Experimental Medicine|2019|133
First magnetic resonance imaging-guided cardiac radioablation of sustained ventricular tachycardia
|Radiotherapy and Oncology|2020|86